Researchers test extended dosing of hepatitis b drug
NCT ID NCT02738008
Summary
This study tested giving nine additional doses of an experimental drug called ARC-520 to people with chronic hepatitis B who had previously responded well to it. All 12 participants continued taking their standard daily hepatitis B medication alongside the ARC-520 injections. The main goal was to check if the extra doses were safe and if they could further reduce the amount of hepatitis B virus in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Hong Kong, 999077, China
-
Research Site 2
Leipzig, 04103, Germany
-
Research Site 3
Busan, 602-739, South Korea
-
Research Site 4
Seoul, 110-744, South Korea
-
Research Site 5
Incheon, 405-760, South Korea
-
Research Site 6
Seoul, 120-752, South Korea
Conditions
Explore the condition pages connected to this study.